Temperature-stable experimental tuberculosis vaccine enters clinical testing

Temperature-stable experimental tuberculosis vaccine enters clinical testing
January 28, 2019 Eric Bosch

Vaccinations have begun in a Phase 1 human clinical trial testing a freeze-dried, temperature-stable formulation of an experimental tuberculosis (TB) vaccine candidate. Continue reading on the National Institutes of Health website.

DF/Net has been working with the Infectious Disease Research Institute (IDRI) in Seattle since 2004: they were our second client! We’ve worked on phase I, II, and II vaccine projects in Central and South America, India, Africa, and the U.S, studying leishmaniasis, TB, flu, and leprosy. IDRI is is a Product Development Partner for the Bill & Melinda Gates Foundation Global Health Clinical Consortium (GHCC), for which DF/Net is a Preferred Provider.

DF/Net is honored to be working with IDRI on this project.